ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Buy: Allogene Therapeutics

01/14/2022 | 01:27pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALLOGENE THERAPEUTICS, INC. -4.34% 7.27 Delayed Quote.-51.27%
KRONOS BIO, INC. -4.57% 3.76 Delayed Quote.-72.33%
ON SEMICONDUCTOR CORPORATION -4.56% 55.83 Delayed Quote.-17.80%
All news about ALLOGENE THERAPEUTICS, INC.
05/10TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confe..
CI
05/10Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines..
AQ
05/09Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc..
GL
05/05Raymond James Adjusts Allogene Therapeutics' Price Target to $13 from $36, Keeps Outper..
MT
05/04TRANSCRIPT : Allogene Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/04ALLOGENE THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
05/04Allogene Therapeutics Reports First Quarter 2022 Financial Results
GL
05/04Allogene Therapeutics Reports First Quarter 2022 Financial Results
AQ
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,13 M - -
Net income 2022 -366 M - -
Net cash 2022 430 M - -
P/E ratio 2022 -2,82x
Yield 2022 -
Capitalization 1 044 M 1 044 M -
EV / Sales 2022 4 731x
EV / Sales 2023 128x
Nbr of Employees 334
Free-Float 55,9%
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | ALLO | US0197701065 | MarketScreener
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 7,27 $
Average target price 26,81 $
Spread / Average Target 269%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-51.27%1 044
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169